TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23594060

Group type: EXPERIMENTAL
Intervention: Home-based psychoeducational program (average of 36.7 hours over 6 months)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Mailed information (provided to all dyads for 12 months)
Number of subjects: 159
Study: 21450567

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT; 85-90% of peak oxygen uptake, VO(2peak))
Number of subjects: 200

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT; 50-60% of VO(2peak))
Number of subjects: 200

Group type: COMPARATOR
Intervention: Recommendation of Regular Exercise (RE)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT)
Number of subjects: 200
Study: 20935337

Group type: EXPERIMENTAL
Intervention: Initial physical activity group (diet and physical activity for 12 months)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Delayed physical activity group (diet for 12 months, physical activity delayed for 6 months)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Both groups (initial and delayed physical activity)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Initial physical activity group
Number of subjects: 130
Study: 18405787

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/d, n=132)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg/d, n=131)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Enalapril plus diuretics
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Amlodipine plus diuretics
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Composite secondary end point
Number of subjects: 263
Study: 15660392

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (180 microg once weekly for 48 weeks)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Number of subjects: 121
Study: 11912091

Group type: EXPERIMENTAL
Intervention: Patellar tendon autograft
Number of subjects: 70

Group type: COMPARATOR
Intervention: Hamstring tendon autograft
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study: 9661633

Group type: EXPERIMENTAL
Intervention: NIS gene expression in primary thyroid carcinomas
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NIS gene expression in follicular thyroid adenomas
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NIS mRNA expression in metastasis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NIS gene expression in differentiated thyroid cancer patients with metastases
Number of subjects: 41
Study: 7662936

Group type: EXPERIMENTAL
Intervention: Multidisciplinary early intervention pilot programme for back injuries
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control wards (1395 nurses)
Number of subjects: 250
Study: 2757695

Group type: EXPERIMENTAL
Intervention: Naloxone administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 0
Study: 3961

Group type: EXPERIMENTAL
Intervention: cedilanid-D
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 7017171

Group type: EXPERIMENTAL
Intervention: 250 mg cinoxacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 g nalidixic acid 4 times daily
Number of subjects: 50
Study: 31104069

Group type: EXPERIMENTAL
Intervention: Thrombomodulin (0.06 mg/kg/d, maximum 6 mg/d) administered as an intravenous bolus or a 15-minute infusion once daily for 6 days (n = 395)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (n = 405)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Thrombomodulin (n = 396)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (n = 404)
Number of subjects: 800
Study: 29162361

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTTs) with 25, 75, and 125 g glucose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoglycemic glucose infusions (IIGI)
Number of subjects: 16
Study: 26859828

Group type: EXPERIMENTAL
Intervention: ART initiation at CD4 counts of 350‐550 cells/mm³
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ART initiation at lower CD4 cell counts
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: High baseline viral load and less education
Number of subjects: 85
Study: 24423245

Group type: EXPERIMENTAL
Intervention: Standard care plus brief education (intervention)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 184
Study: 22687887

Group type: EXPERIMENTAL
Intervention: Web-based multiple computer-tailored smoking cessation program
Number of subjects: 1123

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1123
Study: 19439041

Group type: EXPERIMENTAL
Intervention: Recombinant tissue factor pathway inhibitor (rTFPI)
Number of subjects: 0
Study: 17319797

Group type: EXPERIMENTAL
Intervention: 40 mg etomoxir
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: 80 mg etomoxir
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 15144667

Group type: EXPERIMENTAL
Intervention: Glutamine granules (0.5 g.kg(‐1).d(‐1) for 7 days)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (glycine)
Number of subjects: 120
Study: 12492461

Group type: EXPERIMENTAL
Intervention: Computer touch-screen technology for self-reporting psychosocial information
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Completion of Cancer Needs Questionnaire (CNQ)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Completion of EORTC QLQ-C30
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Completion of Beck Depression Inventory - Short Form (BDI)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Seven-item pen and paper survey for assessing acceptability
Number of subjects: 450
Study: 9661544

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: No intervention (patients without pulmonary hypertension)
Number of subjects: 40
Study: 7655808

Group type: EXPERIMENTAL
Intervention: Trainee-centered training on QI methods with problem-solving oriented methodology (GI)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Traditional training (GII)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No training (GIII)
Number of subjects: 30
Study: 2577460

Group type: EXPERIMENTAL
Intervention: Bendrofluazide (10 mg daily)
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily)
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 22000

Group type: EXPERIMENTAL
Intervention: Slow-release oxprenolol (160 mg)
Number of subjects: 22000
Study: 769697

Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% solution or cream formulation
Number of subjects: 1361

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 1361
Study: 31846073

Group type: EXPERIMENTAL
Intervention: Provisional crown (test)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard healing abutment (control)
Number of subjects: 40
Study: 30795492

Group type: EXPERIMENTAL
Intervention: Risperidone adjunct therapy for 24 weeks
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Risperidone adjunct therapy for 52 weeks
Number of subjects: 93

Group type: COMPARATOR
Intervention: Risperidone adjunct therapy for 0 weeks
Number of subjects: 93
Study: 29079405

Group type: EXPERIMENTAL
Intervention: Incentive condition participants received compensation for taking counseling calls ($30 per call) and for biochemically verified abstinence at the 6-month visit ($40).
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Control participants received no incentive payments.
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Incentive condition participants accepted Wisconsin Tobacco Quit Line treatment calls.
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Incentive participants had a cost/quit/participant of $3,601.37.
Number of subjects: 1900
Study: 26536471

Group type: EXPERIMENTAL
Intervention: Placebo oxygen inhaled through a mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo aspirin swallowed with a pill
Number of subjects: 0
Study: 23524858

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (8 PM)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Timolol 0.5% (or 0.25% for those <3 y old; 8 AM/8 PM)
Number of subjects: 68
Study: 20091317

Group type: EXPERIMENTAL
Intervention: Micronized progesterone (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (100 mg) administered daily by vaginal suppository between 24 and 34 weeks of gestation
Number of subjects: 150
Study: 19863881

Group type: EXPERIMENTAL
Intervention: HX575
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator epoetin‐a
Number of subjects: 0
Study: 17326893

Group type: EXPERIMENTAL
Intervention: Ophthalmic erythromycin ointment (0.5%)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Normal saline (one drop into each eye)
Number of subjects: 138

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 138
Study: 14748035

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical modelling approach for binary outcome data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incorporation of prior data about typical ICCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Consideration of both cluster and individual level covariates
Number of subjects: 0
Study: 12087649

Group type: EXPERIMENTAL
Intervention: Sugar-coated pacifier
Number of subjects: 84

Group type: COMPARATOR
Intervention: Water-moistened pacifier
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control
Number of subjects: 84

Group type: COMPARATOR
Intervention: Oral sucrose solution
Number of subjects: 84
Study: 9793772

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac plus 0.3% tobramycin ophthalmic solution (two eyedrops every 6 hours, n = 44)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.1% diclofenac (Voltaren) plus 0.3% tobramycin (Tobrex) (one drop of each every 6 hours, n = 44)
Number of subjects: 88
Study: 7643263

Group type: EXPERIMENTAL
Intervention: Nasogastric indwelling feeding tubes (placed for up to 3 days)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Orogastric intermittent feeding tubes (placed for each feeding and removed after feeding)
Number of subjects: 93
Study: 2653395

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium slow release (DSR) 100 mg daily
Number of subjects: 846

Group type: COMPARATOR
Intervention: Dextropropoxyphene 180 mg and Paracetamol 1.95 g daily (D&P)
Number of subjects: 846
Study: 407818

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 95
Study: 31823063

Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo (300 mg of corn-starch)
Number of subjects: 17
Study: 27935736

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study: 26247388

Group type: EXPERIMENTAL
Intervention: Attentional Bias (AB) for alcohol-related stimuli
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Automatic Approach/Avoidance tendencies (AA)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 50
Study: 23884037

Group type: EXPERIMENTAL
Intervention: Continuation of lipophilic statins
Number of subjects: 43810

Group type: EXPERIMENTAL
Intervention: Simvastatin (lipophilic statin)
Number of subjects: 43810

Group type: EXPERIMENTAL
Intervention: Atorvastatin (lipophilic statin)
Number of subjects: 43810

Group type: COMPARATOR
Intervention: Hydrophilic statins
Number of subjects: 43810

Group type: COMPARATOR
Intervention: Long-term use of statins (lipophilic or hydrophilic)
Number of subjects: 43810
Study: 21493058

Group type: EXPERIMENTAL
Intervention: 4-week adjuvant high-dose interferon α-2b (arm A: 15 × 10(6)U/m(2)d1-5/w × 4w)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 1-year adjuvant high-dose interferon α-2b (arm B: 15 × 10(6)U/m(2)d1-5/w × 4w + 9 × 10(6)Utiw × 48w)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 158
Study: 19643849

Group type: EXPERIMENTAL
Intervention: Intermittent crossclamp fibrillation
Number of subjects: 195

Group type: COMPARATOR
Intervention: Cardioplegic arrest
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 195
Study: 17606328

Group type: EXPERIMENTAL
Intervention: High cortisol responders exposed to acute psychosocial stress (Trier Social Stress Test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low cortisol responders exposed to acute psychosocial stress (Trier Social Stress Test)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Participants in a rest condition (control)
Number of subjects: 20
Study: 15134765

Group type: EXPERIMENTAL
Intervention: Unexpected disruption consisting of a brief low spatial frequency motion field during the events.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blank-screen disruptions added in the second experiment.
Number of subjects: 0
Study: 12122965

Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg daily)
Number of subjects: 37
Study: 9040545

Group type: EXPERIMENTAL
Intervention: Vitamin A (60 mg)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study: 8424280

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg.kg‐1 i.v.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intralipid 10%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flunitrazepam (0.03 mg.kg‐1 i.v.)
Number of subjects: 20
Study: 3305896

Group type: EXPERIMENTAL
Intervention: Composite cement in mechanically corrugated post spaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite cement in post spaces rinsed with 1 ml of 17% EDTA and 1 ml of 5.25% NaOCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement in mechanically corrugated post spaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement in post spaces irrigated with 1 ml of 40% polyacrylic acid and rinsed with distilled water
Number of subjects: 0
Study: 30078504

Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 204
Study: 26826533

Group type: EXPERIMENTAL
Intervention: Escitalopram treatment for 6 weeks
Number of subjects: 53
Study: 24632986

Group type: EXPERIMENTAL
Intervention: Spaced retrieval combined with errorless learning (SR/EL)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Spaced retrieval only (SR-only)
Number of subjects: 61
Study: 22544598

Group type: EXPERIMENTAL
Intervention: Myth and Denial program session
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Program-delayed assessment group
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study: 21341623

Group type: EXPERIMENTAL
Intervention: Group RD (100 microg dexmedetomidine + 19 ml of 0.25% ropivacaine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group R (19 ml of 0.25% ropivacaine + 1 ml isotonic saline)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group RD
Number of subjects: 60
Study: 17609908

Group type: EXPERIMENTAL
Intervention: Quyu Jiedu Recipe (QJR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Gestrinone (GT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal control group (healthy women)
Number of subjects: 50
Study: 16130860

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (Platinum/Colgate)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7.5% hydrogen peroxide (Day White 2Z/Discus Dental)
Number of subjects: 30
Study: 11999466

Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily (o.d.)
Number of subjects: 311
Study: 10411249

Group type: EXPERIMENTAL
Intervention: Oxygenator coated with albumin in the priming solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxygenator coated with Carmeda
Number of subjects: 60

Group type: COMPARATOR
Intervention: Uncoated oxygenator (noncoated group)
Number of subjects: 60
Study: 7547213

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg i.v. 30 min after cisplatin or 16 mg orally at the end of cisplatin infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Buspirone (60 mg p.o. at the end of cisplatin and 60 mg p.o., 30 min later)
Number of subjects: 0
Study: 1372924

Group type: EXPERIMENTAL
Intervention: Large volume paracentesis (LVP) and infusion of low molecular weight dextran (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aldactone 400 mg/day and furosemide 80 mg/day (n = 20)
Number of subjects: 40
Study: 3895014

Group type: EXPERIMENTAL
Intervention: DGAVP 92 micrograms intranasally TID
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 29310015

Group type: EXPERIMENTAL
Intervention: Resistance training with instability (RTI)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-exercising control
Number of subjects: 39
Study: 27741007

Group type: COMPARATOR
Intervention: Total Parathyroidectomy (TPTX)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total Parathyroidectomy with Autotransplantation (TPTX+AT)
Number of subjects: 100
Study: 25482346

Group type: EXPERIMENTAL
Intervention: ScorpioFlex TKA
Number of subjects: 15

Group type: COMPARATOR
Intervention: NRG TKA
Number of subjects: 15
Study: 23997131

Group type: EXPERIMENTAL
Intervention: Synovectomy
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control
Number of subjects: 187
Study: 21875548

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18500080

Group type: EXPERIMENTAL
Intervention: PRK with MMC 0.002% for 1 minute
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: PRK with MMC
Number of subjects: 44

Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 44
Study: 16805745

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 14725412

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental zinc as zinc sulphate)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 300
Study: 12212254

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 7581831

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined supplement (vitamin E, vitamin C, beta-carotene)
Number of subjects: 0
Study: 2207401

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion after parasympathetic blockade with 30 micrograms/kg intravenous atropine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion before atropine administration
Number of subjects: 21
Study: 6996506

Group type: EXPERIMENTAL
Intervention: Early fiberoptic endoscopy with immediate results
Number of subjects: 95

Group type: COMPARATOR
Intervention: Early fiberoptic endoscopy with results revealed after 4 days
Number of subjects: 95
Study: 31614535

Group type: EXPERIMENTAL
Intervention: Theory of planned behavior (TPB)-based health education intervention with a planning strategy (one-on-one counseling session with a planning sheet)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Theory of planned behavior (TPB)-based health education intervention with a planning strategy
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (CG) received a leaflet only
Number of subjects: 297
Study: 28520668

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 22

Group type: COMPARATOR
Intervention: Stretching comparison
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy comparison group
Number of subjects: 22
Study: 26633093

Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441
Study: 23734871

Group type: EXPERIMENTAL
Intervention: Junior Doctor Dashboard providing feedback on prescription warning information and laboratory alerting acceptance rates, accessed weekly for 4 months.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no automated feedback).
Number of subjects: 86
Study: 21770020

Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at birth
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at 6-week postnatal visit
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Congenital anomalies identified at illness-related visits
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Prevalence of major congenital anomalies
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Prevalence of cardiac anomalies
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Prevalence of neural system anomalies
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Prevalence of musculoskeletal anomalies
Number of subjects: 2365

Group type: EXPERIMENTAL
Intervention: Prevalence of skin anomalies
Number of subjects: 2365
Study: 19318792

Group type: EXPERIMENTAL
Intervention: SNAPPS training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Feedback training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual-and-customary instruction
Number of subjects: 64
Study: 17046377

Group type: EXPERIMENTAL
Intervention: Desogestrel (150 mug)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (100 mug)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (36 women)
Number of subjects: 52
Study: 12894131

Group type: EXPERIMENTAL
Intervention: Alefacept (12 weekly intramuscular or intravenous injections)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Alefacept (2 courses)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Alefacept (single course)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1300
Study: 10703113

Group type: EXPERIMENTAL
Intervention: rhBMP-2/collagen sponge
Number of subjects: 14

Group type: COMPARATOR
Intervention: autogenous iliac crest bone
Number of subjects: 14